The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.
Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...
Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...
How well are you juggling the pillars of good health, including sleep, diet, exercise, relationships and stress management? Check in with yourself today! Each quiz contains 20 questions and takes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback